Quick Takeaways
- JPMORGAN CHASE & CO filed SCHEDULE 13G for KEROS THERAPEUTICS, INC. Common Stock, $0.0001 par value per share (KROS).
- Disclosed ownership: 6.3%.
- Date of event: 31 Mar 2025.
JPMORGAN CHASE & CO - 31 Mar 2025 SCHEDULE 13G Report for KEROS THERAPEUTICS, INC. Common Stock, $0.0001 par value per share (KROS)
- Filing Manager
- JPMORGAN CHASE & CO
- Reporting Manager
- JPMORGAN CHASE & CO.
- Symbol
- KROS
- Shares outstanding
- 41,065,810 shares
- Disclosed Ownership
- 2,587,146 shares
- Ownership
- 6.3%
- Form type
- SCHEDULE 13G
- Filing time
- 02 May 2025, 09:59:54 UTC
- Date of event
- 31 Mar 2025
- Next filing
- 05 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"JPMORGAN CHASE & CO disclosed 6.3% ownership in KEROS THERAPEUTICS, INC. Common Stock, $0.0001 par value per share (KROS) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 02 May 2025, 09:59.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| JPMORGAN CHASE & CO. | 6.3% | 2,587,146 | 2,587,146 | 0 | Rachel Tsvaygoft | Vice President |